• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 3. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 4. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

Recent Advances in the Study of 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide (CAS: 13124-11-3) in Chemical Biology and Pharmaceutical Research

4-(2,4-Dichlorophenyl)-3-thiosemicarbazide (CAS: 13124-11-3) is a thiosemicarbazide derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its dichlorophenyl and thiosemicarbazide functional groups, has been investigated for its diverse biological activities, including antimicrobial, anticancer, and enzyme inhibitory properties. The unique structural features of this molecule make it a promising scaffold for the development of novel therapeutic agents.

Recent studies have focused on elucidating the molecular mechanisms underlying the biological activities of 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent inhibitory effects against Mycobacterium tuberculosis, with a minimum inhibitory concentration (MIC) of 2.5 μg/mL. The researchers attributed this activity to the compound's ability to disrupt mycobacterial cell wall synthesis by targeting key enzymes involved in mycolic acid biosynthesis. These findings suggest potential applications in the treatment of drug-resistant tuberculosis.

In the field of oncology, a 2024 research article in Bioorganic Chemistry reported that 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide shows selective cytotoxicity against various cancer cell lines, particularly breast cancer (MCF-7) and colon cancer (HCT-116) cells. The study revealed that the compound induces apoptosis through mitochondrial pathway activation and ROS generation. Molecular docking studies further suggested strong interactions with Bcl-2 family proteins, providing insights into its mechanism of action at the molecular level.

The compound's enzyme inhibitory properties have also been extensively studied. Research published in European Journal of Medicinal Chemistry (2023) demonstrated significant inhibitory activity against carbonic anhydrase isoforms (CA I, II, IX, and XII), with IC50 values ranging from 0.45 to 1.2 μM. These findings are particularly relevant for the development of treatments for glaucoma, epilepsy, and cancer, where carbonic anhydrase inhibition plays a crucial therapeutic role.

From a chemical synthesis perspective, recent advances have focused on developing more efficient synthetic routes for 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide. A 2024 study in Organic Process Research & Development described a novel one-pot synthesis method with improved yield (85%) and purity (>99%), addressing previous challenges in large-scale production. This methodological advancement is expected to facilitate further pharmacological evaluation and potential clinical translation of this compound.

Despite these promising findings, challenges remain in the development of 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide as a therapeutic agent. Current research is addressing issues related to pharmacokinetic properties, particularly its aqueous solubility and metabolic stability. Several research groups are exploring structural modifications and prodrug approaches to optimize these parameters while maintaining the compound's biological activity.

In conclusion, 4-(2,4-Dichlorophenyl)-3-thiosemicarbazide (CAS: 13124-11-3) represents a versatile scaffold with multiple therapeutic potentials. Recent studies have significantly advanced our understanding of its biological activities and mechanisms of action. Future research directions include structure-activity relationship studies, formulation development, and preclinical evaluation to further explore its therapeutic applications in various disease areas.

• 79-19-6(aminothiourea)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)